Plant- and herb-targeted envelope protein, spike protein, membrane protein, protease inhibitors, ACE-2 receptors, nuclear capsid protein, and endosomal-like parts of a virus.
Piper longum L. Piperaceae, a fruit commonly known as Indian spice kali mirch, has been reported to show antiviral activity against Coxsackie virus type 3 (CVB3) due to the presence of α-pinene, β-pinene, limonene, myrcene, sabinene, camphene, α-thujone, piperitone, caryophyllene, p-cymene, α-terpinene, and piperamide
[21][44]. A study on curcumin described its inhibitory action on viruses in addition to SARS-CoV-2.
Curcuma longa L. (Zingiberaceae) is enriched with curcumenone, bisacumol, bisacurone, curcumenol, curcumadiol, and demethoxycurcumin. Curcumin inhibits SARS-CoV-2 replication in human cells, as previously reported for HIV-AIDS
[21][22][44,45], chikungunya virus, Zika virus, and herpes simplex virus (HSV).
Moreover, curcumin has been reported to inhibit the penetration of SARS-CoV-2 into host cells to prevent infection. The prevention of chikungunya and Zika virus infectivity by curcumin has been reported, and this feature of turmeric may be beneficial for the therapeutic inactivation of COVID-19
[23][46].
Syzygium aromaticum (L.) Merr. & L.M. Perry (Myrtaceae) flowering buds have been reported to contain eugenol, acetyl eugenol, β-caryophyllene, vanillin, eugenin, kaempferol, rhamnetin, and eugenitin, and they have antiviral potential against SARS-CoV-2, herpes simplex virus I, herpes simplex virus 2, and the hepatitis C virus.
A docking study reported that eugenol shows low binding energies with viral proteins; for example, its binding energies were −6.1 and −5.4 kcal/mol for the S protein (PDB ID 6VXX) and M
pro (PDB ID 6LU7), respectively
[24][47]. However, this low binding energy showed a less significant effect than the even lower binding energies of nelfinavir with these proteins, which were −8.8 and −8.2 kcal/mol, respectively.
Sage essential oils as phytomedicines have recently been discussed, particularly as antiseptics and sanitizers. The essential oil in
Salvia officinalis L. has been reported to exert an effect against SARS-CoV in a patient at the Frankfurt University Hospital, showing an IC50 = 870 mg/mL, which was low
[25][26][48,49]. The main chemical compounds in the essential oil extracted from
Laurus nobilis L. that have been reported to inhibit SARS-CoV and HSV-1 replication were 1,8-cineole, beta-ocimene, beta-pinene and alpha-pinene, each with t an IC(50) value of 120 µg/mL
[27][50]. Thus, it can be concluded from previously conducted research that essential oils have limited antiviral activities against viruses, including SARS-CoV-2
[25][48]. Thus, symptomatic alleviation after infection may be achieved by using essential oils such as eucalyptus oil, eugenol, cinnamon oils, and neem oil.
Zingiber officinale Roscoe from Zingiberaceae and rhizome have been reported to contain therapeutic chemicals, including 6-gingerol, 6-shogaol, 6-paradol, zingerol, and gingerol, with activity against SARS-CoV-2 and human respiratory syncytial virus (HSRV). The antiviral potential of
Zingiber officinale Roscoe against viruses, including SARS-CoV-2, has been described on the basis of computational approaches. The results of docking studies have indicated that 6-Sogaol showed binding energies of −5.5 and −5.8 kcal/mol to the S protein (PDB ID 6VXX) and M
pro (PDB ID 6LU7), which were comparable to the binding energies of nelfinavir for these proteins (−8.8 and −8.2 kcal/mol, respectively). In silico studies indicated that eight chemicals extracted from rhizomes of
Alpinia officinarum Hance, Zingiberaceae, and gingerol were potential protease (PLpro) inhibitors of SARS-CoV-2. Thus, the aforementioned studies showed that phytoconstituents or their extracts were SARS-CoV-2 inhibitors, suggesting that these compounds are promising therapeutic molecules against SARS-CoV-2
[28][29][51,52]. The role of
Schizachyrium urceolatum Stapf Poaceae as an antioxidant suggests that cinnamon shows appreciable immunostimulatory activity by increasing phagocytic activity
[30][53].
The root and flower of clove pink, also known as
Dianthus caryophyllus L., has been reported to contain dianthin30, dianthin32, dianthramides, flavonoids against SARS, herpes simplex virus-I (HSV-I), hepatitis-A Virus-27 (HSV-27)
[22][45]. The antiviral activity against herpes simplex virus-I and hepatitis A virus-27 of crude seed extract are found in this plant. At a nontoxic concentration (20 µg/mL), the extract applied to both Vero and HepG-2 cells led to potent antiviral effects on HSV-I and HAV-27, as determined using a plaque infectivity count assay
[22][45].
Dianthus caryophyllus L. as reported to exhibit antiviral activity against HSV-I and HAV-27, so this plant could also be a potential source for antiviral activity against SARS-CoV-2.
The
Phytolacca americana L. Phytolaccaceae plant synthesizes ribosome-inactivating protein (RIP). A single-chain ribosome-inactivating protein has been analyzed. Studies provided evidence showing that exogenous application of RIP inhibits zucchini yellow mosaic virus (ZYMV) infection in squash plants in a concentration-dependent manner
[31][54]. The antiviral activity of the
Mirabilis jalapa L. plant contains 4-hydroxycoumarin, mirabijalones A-D, and 9-o-methyl-4-hydroxyboeravinone B. The root extract of these compounds inhibits the multiplication of tobacco mosaic virus via the inactivation of ribosomes that had been stimulated by the virus
[32][55]. The antiviral effect of
Camellia sinensis (L.) Kuntze extract, also known as green tea, has been reported to inhibit the expression of hepatitis surface antigen (HBsAg) and hepatitis B antigen (HbeAg). Studies reported that the extract exerted an inhibitory effect on intestinal α-glycosidases that are important for processing glycoproteins and glycolipids in viruses
[28][33][34][51,56,57]. Kim et al. reported that the methanolic extracts of
Acanthopanax (Decne. & Planch.) Miq. Araliaceae and
Cimicifuga acemose (L.) Nutt. were administered at doses of 0.9 ± 0.1 μg/mL and 19.4 ± 7.0 μg/mL, inhibiting MHV-A59-type coronavirus, respectively. The IC
50 of the ethanolic extract of
Artemisia annua L. against SARS-CoV BJ-001 was 34.5 ± 2.6 μg/mL
[35][36][58,59].
Euphorbia neriifolia L., Euphorbiaceae enriched with 3-β-friedelanol, 3-β-acetoxy friedelane, friedelin, and epitaraxerol-like chemical compounds has also been described to significantly inhibit HCoV
[37][60]. The IC50 of an aqueous extract with 191.6 ± 8.2 μg/mL of
Isatis indigotica Fortune ex Lindl; Brassicaceae and other bioactive molecules, e.g., 752 μM Indigo, 217 μM Sinigrin, 1210 μM beta-sitosterol, 366 μM aloe emodin, and 8.3 μM Hesperetin, indicated the antiviral potentiality of this plants against SARS-CoV. Among the compounds from this plant that were tested, low-dose hesperetin showed the greatest antiviral molecule activity. The aquas extract of
Polygonum multiflorum Thunb. Polygonaceae (root/vine) has been reported to exhibit significant antiviral activity (IC50 1–10 μg/mL) against SARS-CoV
[29][52]. Chen et al. reported the antiviral effect of a water-based extract of
Toona sinensis (Juss.) against SARS-CoV, which showed efficacy at an IC50 of 30–43 μg/mL
[38][61]. When a 6% Epimedium aqueous extract was administered in the test model it led to no diarrhoeal symptoms
[39][62], and intestinal biopsy sample assays revealed complete eradication of the virus from the intestine of the tested animals. The roots of
Polypodium glycyrrhiza D.C.Eaton (Licorice) have been used as a traditional medicine for bronchitis, peptic ulcers, allergies, inflammation, and asthma for a long time. Licorice root has been known to be a powerful viral infection inhibitor since ancient times
[40][41][42][43][63,64,65,66]. Glycyrrhizic acid, also referred to as glycyrrhizin, is a key chemical compound in the triterpenoid glycoside class of herbs. SARS-CoV has reportedly been suppressed with glycyrrhizin
[44][67]. Replication of clinical isolates of SARS-CoV have been reportedly inhibited by glycyrrhizin more effectively than a number of synthetic antivirals, including mycophenolic acid, pyrazofurin, 6-azauridine, and ribavirin
[45][68]. Many plants and foods contain high levels of the flavonoid quercetin, which shows a wide range of therapeutic and pharmaceutical effects
[46][69]. Both quercetin 3-galactoside and quercetin abrogate the SARS-CoV 3CLpro protease function in vitro
[47][70].
Wen et al. discovered that specific lignoids and abietane-type diterpenoids show the strongest SARS-CoV-2 inhibiting activities, and they are present in
Cryptomeria japonica (Thunb. ex L.f.) D.Don; Cupressaceae
Juniperus formosana Hayata Cupressaceae, and
Chamaecyparis obtusa Siebold & Zucc. Cupressaceae
[48][71]. Moreover, other bioactive substances related to the aforementioned compound classes are present in
Cibotium barometz (L.) J.Sm. Cibotiaceae (dried rhizome),
Gentiana scabra Bunge, Gentianaceae (dried rhizome),
Dioscorea batatas Decne., Dioscoreaceae (tuber),
Taxillus chinensis (DC.) Danser, Loranthaceae (leaf), and
Cassia tora L. Fabaceae (dried seed), which explains the anti-SARS-CoV potential confirmed through a cell-based assay with infected Vero E6 cells at concentrations between 25
[48][71]. Through their potential anti-inflammatory molecules,
Boswellia serrata extracts may be promising compounds for the management of inflammatory complications during COVID-19
[49][72].
The antiviral effect of
Bupleurum falcatum subsp.
cernuum (Ten.) Arcang; Apiaceae (
Radix bupleuri) has been reported to explain the presence of saikosaponins A, B2, C, and D. These active constituents are naturally derived triterpenoid glycosides recovered from the
Radix bupleuri plant. By targeting viruses, these compounds effectively prevent the early stage of HCoV-22E9 infection after facilitating the entry of the virus through viral attachment to the host cell
[44][50][51][67,73,74].
Clinical studies on
Glycyrrhiza glabra L. (Fabaceae) against coronavirus revealed that glycyrrhizin controlled viral SARS-CoV replication. A comparative study was performed using ribavirin, 6-aziridine, pyrazofurin, mycophenolic acid, and glycyrrhizin, to analyze their antiviral activities against coronaviruses (FFM-1 and FFM-2) obtained from clinical patients suffering from SARS. At the end of the study, it was demonstrated that glycyrrhizin at nontoxic concentrations inhibited the replication of SARS-CV; its selectivity index was 67 and its IC50 was 300 mg/mL
[45][52][68,75]. Glycyrrhizin derivatives, such as glycyrrhetinic acid, derivative GL 1, derivative GL 3, derivative GL 9, derivative GL 10, derivative GL11, derivative GL, and derivative GL 13, from
Myosotis radix-palaris A.P.Khokhr; Boraginaceae (
Radix scutellariae), are traditional Chinese medicines. The active constituent of this plant is baicalin. In a molecular docking study, baicalin exhibited a binding energy of −8.46 kcal/mol, which was sufficient to bind the receptor ACE-2 in the host cell; thus, baicalin may be a potential candidate for 2019-nCoV treatment. Recently, in vitro antiviral activity against SARS-CoV-2 3CLpro, causing pandemic disease, showed that
Scutellaria baicalensis potentially inhibited the virus with an EC50 of 0.74 µg/mL
[53][54][76,77]. This citrus plant is abundant in China and has been reported to exhibit anti-SARS activity. Another Chinese herb with reported antiviral activity is
Houttuynia cordata Thunb.; Saururaceae, which inhibited viral protease 3CL activity and blocked the activity of viral enzyme RNA-dependent RNA polymerase
[55][56][78,79]. Similarly,
Rheum and
Polygonum spp. inhibited hepatitis B virus (HBV) in vitro
[56][79]. The papain-like protease (PL
pro), which controls the replication of SARS-CoV, has been described as a potential therapeutic target. Diarylheptanoids isolated from
Alnus japonica Siebold & Zucc.; Betulaceae showed potent (PL
pro) activity, with an inhibitory concentration (IC
50) value of 4.1 µM.
Oleo europaea has also been shown to be a natural antioxidant
[57][58][59][80,81,82].
Thus, the aforementioned compounds clearly indicate the potential of plants/herbs in controlling the disease. Although their compounds are not magic potions to treat disease, they may reduce discomfort and perhaps enhance patients’ overall wellbeing. Only extremely chemically well-characterized and pharmacologically well-researched high-quality preparations are suitable for use as herbal remedies that can be considered medicines. Thorough characterization of formulations in future pharmacological and clinical research is crucial
[60][83].
4. Plants as Biological Factories for the Production of Immunotherapeutics: Applications to SARS-CoV
Various immunomodulators, antibodies, interferons, and other therapeutic proteins have been used in the management of various diseases, including virus-induced diseases. Clinical trials for treatments of MERS and SARS-CoV have revealed the role of interferon in reducing the severity of the diseases caused by these coronaviruses.
Plants have been used as biological factories for the production of immunotherapeutics. Various plant-derived vaccines have been assessed in clinical trials, and a few are now marketed as medications and in conjunction with medical devices for the treatment of infectious and chronic diseases. Plant-based vaccines might enable the rapid production of biological products on an industrial scale, which may help meet needs in urgent situations such as the COVID-19 epidemic. Some vaccinations, including those used for cholera, anthrax, Lyme disease, tetanus, rotavirus, canine parvovirus, and plague, were created through direct particle bombardment or biological means
[61][121]. Vaccines for Ebola, tuberculosis, avian flu, and dengue fever are manufactured indirectly or directly via Agrobacterium-mediated gene transfer
[61][62][121,122].
One study demonstrated that IFN-α inhibited the replication of human- as well as animal-infecting coronaviruses
[63][123]. Another study reported that interferon-α-2a administered with ribavirin increased survival in patients with MERS-CoV
[64][124]. The very first recombinant medicinal protein made from a plant was human interferon, which was created in turnips. Moreover, tobacco plants and potatoes have been used to manufacture human serum albumin for human use. Similarly, tobacco plants were used to generate the first medication (ZMapp) used experimentally to treat Ebola virus infection.
Intravenous gamma globulin (InIg) has also been studied. It was developed in 1970 but gained popularity during the outbreak of SARS in 2003, when it was used extensively in Singapore. However, severe adverse reactions were noticed during its use
[65][125]. Scientists have developed methods for the production of gamma globulin using plant-based molecular farming.
A peptide hormone, thymosin-α-1, has been isolated from thymic tissues, and its immunomodulatory role has been thoroughly explored
[66][126]. Moreover, a synthetic pentapeptide such as thymopentin interacting with the active site in thymopoietin has been found to boost the production of antibodies for hepatitis B vaccines
[67][127]. Plant bioreactors have been successfully applied to the production of thymosin-α-1
[68][69][128,129].
Due to the development and expansion of recombinant techniques, plants are now being assessed as potential alternative platforms for the manufacture of recombinant monoclonal antibodies (mAbs). In a study by Sui et al., r-mAb, a recombinant human monoclonal antibody against the S1 domain of the S protein of SARS-CoV was isolated. Moreover, this mAb had been found to efficiently neutralize SARS-CoV
[70][130]. Recent research demonstrated that plant systems for producing mAbs for immunotherapy have been successfully developed
[71][131].
The immunotherapeutics used as the basis for developing SARS-CoV-2 vaccines are thought to be potentially effective and safe. When considering the potential delivery of SARS-CoV-2 vaccines in the future, current guidelines for immunizing a host must be used
[72][132].
For the first time, the recombinant production of a fully functional human form of the recently identified cytokine IL-37 in plant cells has been reported, with the cytokine functioning as a fundamental suppressor of innate immunity. Interleukin 37 (IL-37), a recently identified member in the interleukin (IL)-1 class, is essential for controlling innate inflammation and inhibiting acquired immunological responses and, therefore, it shows great potential for treating a variety of autoimmune diseases and inflammatory diseases
[73][133]. Recombinant IL-7 is a potential immune therapeutic that acts to promote the proliferation of naive and memory T cells (CD8+ and CD4+ T cells) and may be effective in managing SARS-CoV-2 viral infection. IL-6 is a key mediator of inflammation in COVID-19, and its receptor antagonist (sarilumab/tocilizumab) and IL-6 inhibitors (clazakizumab/siltuximab/sirukumab) have been described as potential immunotherapeutics to manage SARS-CoV-2 viral infections
[74][134].
The IL-1 inhibitors canakinumab (MoAb anti-IL-1beta) and anakinra (recombinant IL-1 receptor) inhibited IL-1β, a proinflammatory cytokine
[75][76][135,136]. Other significant immunotherapeutic IL-1 inhibitors, such as canakinumab (MoAb anti-IL-1beta) and anakinra (a recombinant IL-1 receptor), as well as IL-18 inhibitors, have been reported to inhibit IL-1β. Suppression of signaling that triggers the cytokine stimulation of cytokines such as IL-7 and alters Type I IFN levels significantly enhanced the risk of thromboembolism after treatment with JAK/STAT inhibitors such as ruxolitinib, baricitinib, and tofacitinib
[77][137]. Anti-VEGF, complement factor C3, C5, and complement system inhibitors are other classes of immune therapeutics that may be effective against COVID-19. Bamlanivimab antibodies have also been described as being effective against the spike protein of SARS-CoV-2. Tomato plants have been examined for use in the development of SARS vaccines; specifically, their ability to express SARS-CoV nucleocapsid proteins, and their immunogenicity for the development of vaccines have been assessed. A COVID-19 vaccine is now being developed by the Kentucky Bio-Processing Company, a British American Tobacco (BAT) subsidiary, using tobacco plants to express the SARS-CoV-2 protein subunit. The receptor binding protein or the sequence of the S1 protein (full polypeptide) may be the intended vaccine target
[49][72]. Hence, these findings indicate that plants have enormous promise for the low-cost and high production of biologically active viral inhibitors.